PHESGO® is a subcutaneous combination of pertuzumab and trastuzumab for HER2-positive breast cancer, designed to reduce treatment time.
Related products
Ozempic 1mg Injection (UK)
Semaglutide
Ozempic 0.25mg Injection (UK)
Semaglutide


















